Mirna Therapeutics decreases proposed IPO deal size
Mirna Therapeutics, which is developing microRNA replacement therapies for liver cancer, lowered the proposed deal size for its upcoming IPO on Wednesday. The Austin, TX-based company now plans to raise $44 million by offering 6 million shares at a price of $7. The company had previously filed to offer 5 million shares at a range of $13 to $15.
Mirna Therapeutics, which was founded in 2007, plans to list on the Nasdaq under the symbol MIRN. Mirna Therapeutics initially filed confidentially on 3/12/2014. Citi and Leerink Partners are the joint bookrunners on the deal.
The article Mirna Therapeutics decreases proposed IPO deal size originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.